Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions

Even when grown under identical conditions, different strains of the same mushroom species, Psilocybe cubensis, vary dramatically in their psychedelic compound content. Total tryptamine concentrations ranged more than 7.8-fold across 14 strains, from 2.62 to 20.65 mg per gram of dried mushroom. Psilocybin was always the most abundant compound. Individual mushrooms from the same strain also showed substantial variation, with psilocybin levels differing by 12.81% to 23.39% between fruiting bodies. This biochemical variability, both between strains and within a single strain, makes it difficult to standardize whole mushroom preparations for research or therapeutic use, emphasizing the need for careful strain selection, chemical profiling, and precise dosing.

Study at a glance

Abstract

Psilocybin-producing mushrooms exhibit considerable biochemical diversity, yet the extent of variability among strains within a single species under standardized conditions remains insufficiently characterized. In this study, we quantified psilocybin, psilocin, baeocystin, norbaeocystin, aeruginascin, and norpsilocin in the fruiting bodies of 14 distinct strains of Psilocybe cubensis. The mushroom strains were cultivated, dried, extracted, and analyzed under uniform laboratory conditions. Despite strict methodological standardization, total tryptamine concentrations varied by more than 7.8-fold among strains (from 2.62 to 20.65 mg/g), with psilocybin consistently emerging as the dominant compound. Analysis of individual fruiting bodies within the selected strains revealed substantial intra-strain variability, with coefficients of variation for psilocybin ranging from 12.81% to 23.39% between individual fruiting bodies. These findings demonstrate that both inter- and intra-strain biochemical heterogeneity persist even under controlled conditions, underscoring the challenges of standardizing whole mushroom preparations for research or therapeutic use. Our results highlight the importance of strain selection, rigorous chemical profiling, and dosing precision in future pharmacological and clinical applications of P. cubensis.